Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393071 | 1.00 | NPC1 (0.49) | NPC1ASH1LHTR2AKIF11PARP1 | |
| SCHEMBL393070 | 1.00 | NPC1 (0.49) | NPC1ASH1LHTR2AKIF11PARP1 | |
| SCHEMBL391137 | 0.87 | NPC1 (0.50) | NPC1ASH1LKIF11PARP1GPR84 | |
| SCHEMBL391138 | 0.87 | NPC1 (0.50) | NPC1ASH1LKIF11PARP1GPR84 | |
| SCHEMBL391136 | 0.87 | NPC1 (0.50) | NPC1ASH1LKIF11PARP1GPR84 | |
| SCHEMBL5349191 | 0.86 | NPC1 (0.49) | NPC1ASH1LKIF11PARP1GPR84 | |
| SCHEMBL1173868 | 0.84 | NPC1 (0.54) | NPC1ASH1LKIF11PARP1GPR84 | |
| SCHEMBL51234 | 0.83 | NPC1 (0.53) | NPC1ASH1LKIF11PARP1GPR84 | |
| SCHEMBL393098 | 0.77 | KIF11 (0.46) | HTR2AKIF11PARP1RAB9AGSK3B | |
| SCHEMBL393099 | 0.77 | KIF11 (0.46) | HTR2AKIF11PARP1RAB9AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121707-B1 | ANTIVIRAL INDOLES | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-12-05 | — | — | EP | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-7767660-B2 | Antiviral indoles | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-08-03 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20080214522-A1 | Antiviral indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | NPC1 1532/4885ASH1L 2688/4885HTR2A 264/4885 |
| US-20080214522-A1 | Antiviral indoles | IDO1, ZC3HAV1, YBX1 | NPC1 1529/4885ASH1L 2504/4885HTR2A 278/4885 |
| US-20090136449-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | NPC1 1196/4885ASH1L 3960/4885HTR2A 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.